<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184232</url>
  </required_header>
  <id_info>
    <org_study_id>IBCE_DC1(BLAD)</org_study_id>
    <nct_id>NCT04184232</nct_id>
  </id_info>
  <brief_title>Treatment of Recurrent Bladder Cancer With Dendritic Cells</brief_title>
  <official_title>Treatment of Recurrent Bladder Cancer With Autologous Monocyte-derived Dendritic Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belarusian State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of recurrent bladder cancer with dendritic cells
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy evaluation</measure>
    <time_frame>1 year</time_frame>
    <description>1 year relapse free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Dendritic cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with the recurrent bladder cancer receiving standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic cells</intervention_name>
    <description>Autologous dendritic cells primed with muc-1/wt-1 peptides</description>
    <arm_group_label>Dendritic cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard treatment according to the Clinical protocols</intervention_name>
    <description>Standard treatment of bladder cancer according to the Clinical protocols</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Dendritic cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of pTa bladder cancer;

          -  Patient who require repetitive transurethral resection;

          -  Expression of muc-1/wt-1 by the tumor;

          -  EGOC 0-3;

        Exclusion Criteria:

          -  any medical condition which can be associated with the high risk for the patient;

          -  pregnancy/lactation;

          -  chronic infections, including hepatitis B/C, tuberculosis, HIV
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Hancharou, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Director, the Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander V Prokharau, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Head of the chair, Belarusian State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrei Y Hancharou, Dr</last_name>
    <phone>+375296248972</phone>
    <email>andrei.hancharou@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalia G Antonevich, Dr</last_name>
    <phone>+375295897406</phone>
    <email>antonevich.n@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus</name>
      <address>
        <city>Minsk</city>
        <zip>220072</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei Y Hancharou, Dr</last_name>
      <phone>375296248972</phone>
      <email>andrei.hancharou@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Natalia G Antonevich, Dr</last_name>
      <phone>+375295987406</phone>
      <email>antonevich.n@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 1, 2019</study_first_submitted>
  <study_first_submitted_qc>December 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder Cancer</keyword>
  <keyword>Dendritic cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

